The project, titled Liver Immunocompetent Volumetric Engineering (LIVE), aims to address the shortage of donor organs by ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...

The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

(Nanowerk News) When biomedical researchers need to test their latest ideas, they often turn to engineered human tissue that mimics the responses in our own bodies. It’s become an important ...

Johns Hopkins Medicine scientists who arranged for 48 human bioengineered heart tissue samples to spend 30 days at the International Space Station report evidence that the low gravity conditions in ...

The intricacies of excitable tissues, including cardiac, nervous, and skeletal muscle systems, pose substantial challenges in creating artificial analogs that can replicate their bioelectrical, ...

Johns Hopkins Medicine scientists who arranged for 48 human bioengineered heart tissue samples to spend 30 days at the International Space Station report evidence that the low gravity conditions in ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...